Ace­lyrin's IPO is an 'N of 1', in­dus­try in­sid­ers say, as 50+ biotechs are still wait­ing for their mo­ment on the mar­kets

Cal­i­for­nia drug de­vel­op­er Ace­lyrin land­ed on the Nas­daq Fri­day morn­ing in one of the largest biotech de­buts since 2021, at $540 mil­lion, but the ring­ing of the bell is not like­ly to her­ald a rush-to-mar­ket like the pan­dem­ic’s first year.

Ace­lyrin’s stock $SLRN jumped about 28% in trad­ing on Fri­day.

Ace­lyrin’s up­sized ini­tial pub­lic of­fer­ing is still a rar­i­ty in a cap­i­tal mar­ket ham­pered by high-in­ter­est rates, a bank­ing cri­sis, the war in Ukraine and oth­er macro chal­lenges, ac­cord­ing to in­dus­try ex­ec­u­tives and in­sid­ers who spoke with End­points News.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.